EBN treatment significantly ameliorated hyperandrogenism and gonadotropin imbalance in PCOS rats: it reduced elevated serum luteinizing hormone (LH) and testosterone levels, lowered the LH/FSH ratio, and increased suppressed follicle-stimulating hormone (FSH) and estradiol (all <i>p</i> < 0.05 vs. model control). This evidence concerns the gene BRD2 and hyperandrogenism.